Vasculogenesis Driven by Bone Marrow-Derived Cells Is Essential for Growth of Ewing's Sarcomas

Ling Yu1, Bing Su3, Mario Hollomon1, Yong Deng3, Valeria Facchinetti2, and Eugenie S. Kleinerman1

Abstract

The role of vasculogenesis as opposed to angiogenesis in tumor formation has been little explored genetically. Endothelial cells that lack the MEK kinase MEKK3 cannot form vessels. In this study, we employed mice with hematopoietic deletions of the Mekk3 gene to evaluate the importance of vasculogenesis in the formation of Ewing's sarcoma tumors. Bone marrow cells (BM) from LacZ–/– Mekk3-deficient conditional knockout mice (Mekk3Δflox/− mice) were transplanted into irradiated nude mice before injection of Ewing's sarcoma cells. Because the grafted Mekk3Δflox/− BM cells cannot contribute to vessel development in the same way as the host Mekk3+/+ endothelial cells, angiogenesis is normal in the model whereas vasculogenesis is impaired. Four weeks after BM transplant, Ewing's sarcoma TC71 or A4573 cells were injected, and tumor growth and vessel density were compared. Strikingly, chimeric mice transplanted with Mekk3Δflox/− BM exhibited a reduction in tumor growth and vessel density compared with mice transplanted with Mekk3Δflox/+ BM cells. Mekk3Δflox/− cells that were LacZ-positive were visualized within the tumor; however, few of the LacZ+ cells colocalized with either CD31+ endothelial cells or desmin+ pericytes. Quantification of double-positive LacZ+ and CD31+ endothelial cells or LacZ+ and desmin+ pericytes confirmed that chimeric mice transplanted with Mekk3Δflox/− BM were impaired for tumor vessel formation. In contrast, siRNA-mediated knockdown of Mekk3 in TC71 Ewing's sarcoma cells had no effect on tumor growth or vessel density. Our findings indicate that vasculogenesis is critical in the expansion of the tumor vascular network. Cancer Res; 70(4); 1334–43. ©2010 AACR.

Introduction

New blood vessel formation is critical for tumor growth and metastasis (1). Endothelial cells play an essential role in this process (2–5). We previously showed that in addition to angiogenesis, the migration of bone marrow (BM) cells into the Ewing's sarcoma tumor and their subsequent differentiation into endothelial cells and pericytes (vasculogenesis) contributes to the growth of Ewing's sarcoma (6, 7). It is well established that inhibiting angiogenesis suppresses tumor growth (8, 9). However, the consequences of blocking vasculogenesis are unclear. Evaluating the importance of BM cells and vasculogenesis to tumor growth requires an in vivo model in which vasculogenesis is selectively blocked but local angiogenesis can occur. Mitogen-activated protein kinases are common mediators in the signal transduction pathways from membrane to nucleus. These kinases sequentially activate the downstream kinases and relay signals from extracellular agonists to the designated targets. Mekk3 is a Ser/Thr protein kinase of the mitogen-activated protein kinase kinase gene family (10, 11). Mekk3 is involved in early embryonic cardiovascular and blood vessel development. Deletion of Mekk3 is embryonically lethal at embryonic day (E) 9.5 (12). The Mekk3-deficient yolk sacs have few or no vessels, indicating that this gene plays an essential role in embryonic blood vessel formation. Moreover, cells that lack Mekk3 do not form normal vessels.

To evaluate the importance of vasculogenesis in the growth and development of Ewing's sarcoma, we used Mekk3-deleted BM cells from Mekk3Δflox/− conditional knockout mice as the donor cells to reconstitute irradiated Mekk3+/+ nude mice before tumor injection. Our rationale was that Mekk3-deleted (Mekk3Δflox/−) BM cells cannot participate in vasculogenesis, yielding a model in which vasculogenesis is blocked in the experimental group but angiogenesis in both the experiment and control groups is equal. If vasculogenesis is critical, tumor growth in the Mekk3Δflox/− BM–transplanted mice will be smaller compared with tumors from Mekk3Δflox/+ BM–transplanted mice. Here, we show that Mekk3Δflox/− BM cells do not participate in tumor vessel formation and that tumor growth is significantly impaired when vasculogenesis is inhibited.

Materials and Methods

Mice

* Tie2-GFP-Mekk3Δflox/+ mice. Tie2-GFP mice express green fluorescent protein (GFP) under the direction of the endothelial-specific receptor tyrosine kinase (Tiek, formerly, Tie2) promoter (13). Tie2-GFP mice were crossed with Mekk3Δflox/+ mice (12) to create Tie2-GFP-Mekk3Δflox/+ mice. Male and female...
Tie2-GFP-Mekk3+/− mice were set up for time mating to get Tie2-GFP-Mekk3−/− or Tie2-GFP-Mekk3+/− day 9.5 embryos. Mekk3lopfloxed−/− mice (15) were crossed with Rosa26R mice to generate Mekk3lopfloxed+/−/Rosa26R mice. Mekk3lopfloxed−/− mice were crossed with Cre-ER mice to generate Cre-ER/Mekk3+−/− mice. These mice were then crossed with Mekk3lopfloxed−/− Rosa26R mice to yield Mekk3lopfloxed+/Cre-ER+/−R26R and Mekk3lopfloxed+/Cre-ER−/−R26R mice. Before BM transplantation, these mice were injected i.p. with tamoxifen (2 mg) in 100 μL corn oil every 48 h for 14 d to delete the floxed-Mekk3 gene, generating Mekk3lopfloxed+−/− and Mekk3lopfloxed−/− mice. The Cre recombinase activation after tamoxifen was monitored by lacZ expression resulting from the deletion of a loxP-flanked DNA STOP sequence upstream of the lacZ gene at the Rosa26 locus (14, 16).

Isolation of Mekk3+/− Tie2-GFP and Mekk3−/− Tie2-GFP Endothelial Cells from E9.5-10.5 Embryos and Yolk Sacs

To obtain Tie2-GFP-Mekk3+/− and Tie2-GFP-Mekk3−/− embryos and yolk sacs, Tie2-GFP-Mekk3−/− female mice were set up for time mating with Tie2-GFP-Mekk3−/− male mice (12). Vaginal-plugged female mice were sacrificed on day 9.5-10.5. Embryos and yolk sacs were dissected to remove decidu and Reichert’s membrane. A small piece of yolk sac was removed from each embryo for immediate PCR genotyping. After PCR genotyping, Tie2-GFP-Mekk3+/− and Tie2-GFP-Mekk3−/− yolk sacs were minced into small pieces by repetitive pipetting before incubating with 1 mL of digestion cocktail containing 2 μg/mL collagenase A and 25 μg/mL DNase A (Sigma Chemical) in DMEM (Invitrogen/Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 1 mmol/L sodium pyruvate, 2× MEM vitamins, 1× nonessential amino acids, and 2 mmol/L glutamine (Invitrogen/Life Technologies). The cells were cultured for 1 wk. Endothelial cells and endothelial precursor cells were isolated by sorting for GFP+ cells (17).

Vessel Formation Assay In vivo

GFP+ endothelial cells (5 × 10^5) isolated from Tie2-GFP-Mekk3+/− or Tie2-GFP-Mekk3−/− embryos and yolk sacs were placed in 0.5 mL of Matrigel (BD Biosciences-Discovery Labware). This Matrigel was injected s.c. into nude mouse femurs. Mice were sacrificed 4 wk later. Matrigel plugs were removed, frozen, and analyzed by immunohistochemistry using rat anti-mouse CD31 (BD Bioscience Pharmingen).

Western Blot Analysis

BM cells, heart, lung, kidney, and liver from the Mekk3Δfloxed+−/− and Mekk3Δfloxed−/− mice were homogenized in Triton X-100 lysis buffer with protease and phosphatase inhibitors, and supernatants were harvested. The protein content of each lysate was determined using the Bradford reagent (Bio-Rad Lab). Tissue lysate (30 μg) was resolved by SDS-PAGE. The gels were then electroblotted onto Hybond-ECL nitrocellulose membranes (Amersham). Specific protein bands were detected with monoclonal mouse anti-Mekk3 antibody (BD Transduction Laboratories). Protein loading was assessed with the monoclonal β-actin antibody (Sigma Chemical)

using chemiluminescence and Western blotting analysis (Amersham).

PCR Analysis for Mekk3 Genotypes

Genomic DNA from 7-day-old mouse tails or BM from donor and recipient mice were isolated and amplified by PCR. The PCR primers used were as follows: P1 (5′-TCGCAAGC- CATCGCCTTC-3′), P2 (5′-ATGTAAGGTGAGATTGTGCTTTTGCATGTGAAGCTTGGGGATTTTG-3′), P3 (5′-TTGGTAGACTGACTGTCAGAC-3′), and P4 (5′-TTTGCGATCGGGACATCA-3′). Primer combination P1, P2, and P3 yields amplified fragments of 1,000 bp (Mekk3 floxed), 900 bp (Mekk3 wild-type), and 830 bp (Mekk3 knockout). Primer combination P3 and P4 yields amplified fragments of 1,500 bp (Mekk3 floxed), 1,300 bp (Mekk3 wild-type), and 650 bp (Mekk3 Δfloxed), which represents the deleted allele following tamoxifen treatment. Two separate PCR assays are necessary because one assay cannot detect all four alleles.

Matrigel Plug Assay

Mekk3lopfloxed+−/− and Mekk3lopfloxed−/− mice were injected s.c. at the abdominal midline with 0.6 mL of Matrigel (BD Biosciences-Discovery Labware). Tamoxifen (2 mg) was administered daily for 14 d. Mice were sacrificed, and the Matrigel plugs were removed, frozen, fixed with acetone and chloroform, incubated in 4.5% fish gelatin (Aurion) for 20 min to block nonspecific protein, and then analyzed by immunohistochemistry. Blood vessels were visualized by immunohistochemistry using rat anti-mouse CD31 as the primary antibody and goat anti-rat Texas red (Jackson Immunoresearch Lab) as the secondary antibody. Hoechst 33342 (1:10,000 in PBS; Molecular Probes) was used for nuclear staining. The mean vessel density (MVD) was determined by averaging the number of CD31+ vessels in five random high-power microscopic fields from different Matrigel sections.

Cell Lines and Lewis Lung Carcinoma 3LL Mouse Tumor Model

TC71 and A4573 human Ewing’s sarcoma cells and Lewis lung carcinoma 3LL cells were cultured as described (6, 7, 18). 3LL cells (10^6 in 0.1 mL) were injected into the right and left flanks in Mekk3Δfloxed+−/− Cre-ER+R26R and Mekk3Δfloxed−/− Cre-ER-R26R mice from the same litter.

Ewing’s Sarcoma Mouse Model and BM Transplantation

BM cells from the Mekk3Δfloxed+/− Cre-ER+R26R and Mekk3Δfloxed−/− Cre-ER-R26R mice are LacZ+. These mice were treated with 2 mg of tamoxifen every 48 h for 14 d to achieve deletion of the floxed Mekk3. BM from Mekk3Δfloxed+−/− and Mekk3Δfloxed−/− mice were obtained by flushing the femur and tibia with PBS containing 5% fetal calf serum. Freshly isolated BM cells (5 × 10^6 in 100 μL PBS) were injected into the lateral tail vein of 6-wk-old female nude mice that had been irradiated with 8.0 Gy using an external cesium source (137Cs Mark 1 irradiator, J.L. Shepherd & Associates).

Four weeks after BM transplantation, mice were injected s.c. with 2 × 10^6 TC71 or A4573 cells in 100 μL of PBS. Mekk3Δfloxed+−/− BM–transplanted mice were
injected with 2 mg of tamoxifen every 48 h to maintain deletion of floxed Mekk3, thereby maintaining the Mekk3Δflox/+ genotypes and Mekk3Δflox/− genotypes. Tumor diameter was measured every other day with calipers. Tumor volumes were calculated as 
\[ v = \frac{1}{2}ab^2, \]
in which \( a \) is the longer diameter and \( b \) is the shorter diameter. The chimeric mice were euthanized 3 wk after tumor cell injection. Tumor tissue was analyzed by immunohistochemistry.

**Immunohistochemistry and LacZ Staining**

Tumor specimens from Mekk3Δflox/+ and Mekk3Δflox/− BM–transplanted mice were fixed and cryoprotected in sucrose (35%) overnight, embedded in Tissue-Tek optimum cutting temperature compound, and frozen. LacZ staining was done (19–21). Immunohistochemistry using anti–PECAM-1/CD31 antibody (clone MEC13.3; Pharmingen) or anti-desmin (Abcam) on LacZ-stained tissues was performed followed by counterstaining with nuclear fast red (17, 22). The MVD and mural cell density was determined by averaging the number of CD31 or desmin and LacZ double-positive cells in five random high-power microscopic fields from different tumors.

**Expression Plasmids and Transfection**

siRNA expression vector pSilencer2.1-U6 hygro was purchased from Ambion. siRNA-expressing plasmids targeting human Mekk3 mRNA GTGCAGAAAATTCCTTGTC (23) were annealed at 90°C for 3 min, cooled to 37°C, and incubated for 1 h. The annealed dsDNA oligonucleotides were ligated between BamHI and HindIII sites on the pSilencer2.1-U6 hygro vector. The control vector (si-) was constructed by inserting a sequence that expresses an siRNA with limited homology to sequences in the human and mouse genomes. Transfection of TC71 cells was performed with Lipofectamine 2000 (Invitrogen/Life Technologies). Transfected clones were selected in 400 μg/mL hygromycin B (Invitrogen/Life Technologies). Human Mekk3 expression in the stable clones was quantified by Western blot.

**In vivo Experiments Using TC71/Mekk3 si-transfected Clones**

TC71, TC71/si-control, TC71/Mekk3 si-clone 8, or TC71/Mekk3 si-clone 10 cells (2 × 10⁶) were injected s.c. into four groups of nude mice. Tumor growth was quantified every other day. All the tumors were harvested on day 27 and frozen sections were stained using rat anti-mouse CD31 (primary antibody) and goat anti-rat Texas red (secondary antibody). Hoechst 33342 (1:10,000 in PBS) was used for nuclear staining. The MVD was determined by averaging the number of CD31+ cells in five random high-power microscopic fields. Apoptotic cells were quantified using terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.

**Results**

**Mekk3 deficiency inhibits the formation of normal vessel structures.** Endothelial cells from Tie2-GFP-Mekk3+/− and Tie2-GFP-Mekk3−/− E9.5 yolk sacs were isolated and injected with Matrigel s.c. into nude mice. Vessel formation was assessed after 2 weeks. Mekk3−/− endothelial cells formed
typical round vessels (Fig. 1A), whereas Mekk3−/− endothelial cells failed to form vessel structures (Fig. 1B).

Because deletion of Mekk3 is embryonically lethal (12), we elected to use tamoxifen-dependent, Cre-mediated Mekk3 deletion in Mekk3Δflox− Cre-ER-R26R mice to obtain Mekk3-deleted (Mekk3Δflox−) BM cells. Mekk3Δflox− BM cells from tamoxifen-treated Mekk3Δflox+ Cre-ER-R26R mice were used as the control. To confirm Mekk3 deletion, mice were sacrificed 2 weeks after tamoxifen treatment. Western blotting showed no Mekk3 in BM cells, heart (Fig. 2A), lung, kidney, and liver (data not shown) from the Mekk3Δflox− mice. By contrast, MEKK3 was present in the cells and organs taken from the Mekk3Δflox+ mice.

Having confirmed that we can successfully create Mekk3Δflox− mice with no cellular expression of MEKK3, we next evaluated whether new blood vessel formation could be induced. Anti-CD31 staining was assessed 2 weeks after Matrigel implantation. Matrigel plugs excised from Mekk3Δflox− mice showed a significant decrease in vessel density compared with those from Mekk3Δflox+ control mice (Fig. 2B). These data confirm that the ability of endothelial cells to form vessels is impaired following deletion of Mekk3.

To confirm that tumor vessel formation was also impaired in mice in which Mekk3 was deleted, we injected 3LL lung cancer cells into Mekk3Δflox− and Mekk3Δflox+ control mice. Rapid tumor growth was seen in the Mekk3Δflox− control mice. By contrast, no tumor growth was seen in the Mekk3Δflox− mice, confirming that this gene is also critical for tumor vessel formation (Fig. 2C). This Mekk3Δflox− mouse model, however, could not be used to assess the importance of vasculogenesis in tumor vessel development because both angiogenesis and vasculogenesis are inhibited. Furthermore, no assessment could be performed with regard to Ewing’s sarcoma, as human tumor cells will not grow in immunocompetent mice.

Deletion of Mekk3 in BM cells inhibits vasculogenesis and tumor growth. We showed that Mekk3-deficient cells do not form blood vessels and that Mekk3-deficient mice do not support tumor growth. We next used our previously described Ewing’s sarcoma transplant model (6) to selectively inhibit vasculogenesis to determine the importance of BM cells in the formation of tumor blood vessels. Recipient nude

Figure 2. Tamoxifen-induced deletion of Mekk3 in Mekk3Δflox− Cre-ER mice results in decreased vessel formation and tumor growth in vivo. BM cells and heart (A) were obtained from Mekk3Δflox+ Cre-ER and Mekk3Δflox− Cre-ER mice 2 wk after tamoxifen administration. The resulting Mekk3Δflox+ and Mekk3Δflox− cells were assessed for Mekk3 expression by Western blot. B, following tamoxifen treatment, mice were injected with Matrigel. The Matrigel plugs were excised 2 wk later and assessed by immunohistochemistry using CD31. The average number of CD31+ vessels was calculated by counting five random high-power microscopic fields from different Matrigel plug sections. C, 3LL cells were injected into the Mekk3Δflox+ and Mekk3Δflox− mice 2 wk after tamoxifen administration. Tumor growth was assessed 3 wk after tumor cell injection. Error bars represent SD.
mice were lethally irradiated and then transplanted with BM cells from either the Mekk3Δflox/+ or Mekk3Δflox− mice. The absence of Mekk3 in the Mekk3Δflox− BM cells was confirmed as described in Fig. 2A before transplant. Mekk3Δflox/+ BM cells were positive for Mekk3 and served as the control transplant cells. Engraftment was confirmed 4 weeks after transplant by demonstrating the absence of Mekk3 in the BM cells of the Mekk3Δflox− BM–transplanted mice (Fig. 3). Mice were then injected with TC71 or A4573 cells, and tumor growth was monitored. Because nude mice are Mekk3Δflox−, the local endothelial cells can participate in vascular expansion. However, because the Mekk3Δflox− BM cells lack Mekk3, their ability to contribute to tumor vessel formation (vasculogenesis) is impaired. This experimental design results in selective inhibition of vasculogenesis. Both TC71 and A4573 tumor growth were impaired in the Mekk3Δflox− BM–transplanted mice compared with the mice transplanted with Mekk3Δflox/+ BM cells (Fig. 4A and C). The tumors from the Mekk3Δflox−/− BM–transplanted mice remained small and stable over 17 to 21 days, and seemed to be less vascular in addition to being smaller (Fig. 4B and D).

Because the BM cells from the donor mice were LacZ+ β-gal staining was used to distinguish cells of donor origin from cells of the host. Colocalization of LacZ and CD31 on tumor vessels was seen in tumors excised from the Mekk3Δflox/+ BM–transplanted mice (Fig. 5A). Whereas Lac Z+ cells were visualized within the tumor in the Mekk3Δflox+/− BM–transplanted mice, very few of these cells colocalized with the CD31+ cells (Fig. 5A). Quantification of double-positive LacZ and CD31 cells confirmed that BM cell contribution to tumor vessel formation was impaired following deletion of Mekk3 (Fig. 5A). These data indicate that whereas the Mekk3-deficient BM cells were able to migrate to the tumor area, their contribution to tumor vessel formation was minimal.

To confirm that angiogenesis was at a similar level in Mekk3Δflox+/+ and Mekk3Δflox− BM–transplanted mice, we quantified the number CD31+/LacZ+ vessels in the tumors. CD31+/LacZ− represent tumor vessels with no BM-derived cells and thus can be used as a way to quantify local angiogenesis. There was no difference in the number of CD31+/LacZ− vessels (Fig. 5B). These data indicate that the angiogenesis process was similar in the two groups, confirming that the inhibition in tumor growth was secondary to the defect in vasculogenesis.

Deletion of Mekk3 inhibits the contribution of BM-derived mural cells/pericytes to Ewing’s sarcoma vasculature. Interaction between endothelial cells and mural cells/pericytes plays an important role in vascular formation (24). We showed that BM-derived mural cells/pericytes contribute to Ewing’s sarcoma vessel development (7, 25). Tumors were therefore analyzed by immunohistochemistry for the presence of BM-derived mural cells/pericytes. Colocalization of LacZ+ (donor BM cells) and desmin+ cells (mural cell/Smooth muscle cells) was analyzed by Western blot (A) and genotyping (B and C). B, PCR primers P1, P2, and P3 were used to detect the floxed Mekk3 allele (wt, 900 bp), and smaller (Fig. 4B and D).
pericytes marker) allowed us to quantify BM-derived mural cells/pericytes to contribute to the tumor vascular structure (Fig. 5C). The quantification of double-positive cells in the tumors from control $\text{Mekk3}^{\Delta\text{floxed}/+}$ BM–transplanted mice (Fig. 5C) confirmed our previous findings that BM-derived mural cells/pericytes contribute to tumor vessel formation (7, 25). Deletion of $\text{Mekk3}$ inhibited this process. Very few BM-derived mural cells/pericytes were detected in the tumor vessels from the $\text{Mekk3}^{\Delta\text{floxed}/-}$ BM–transplanted mice (Fig. 5C). By contrast, macrophage marker F4-80 staining showed no difference between the tumors from mice transplanted with $\text{Mekk3}^{\Delta\text{floxed}/-}$ versus $\text{Mekk3}^{\Delta\text{floxed}/+}$ BM cells (data not shown).

**Figure 4.** Deletion of Mekk3 in BM cells inhibited tumor growth. $\text{Mekk3}^{\Delta\text{floxed}/+}$ or $\text{Mekk3}^{\Delta\text{floxed}/-}$ BM cells were injected into lethally irradiated nude mice. Following engraftment, mice were injected with TC71 or A4573 cells. TC71 (A) and A4573 (C) tumor growth was monitored for 3 wk. Error bars represent SD. Representative TC71 (B) and A4573 (D) tumors from $\text{Mekk3}^{\Delta\text{floxed}/+}$ BM–transplanted mice (top) and $\text{Mekk3}^{\Delta\text{floxed}/-}$ BM–transplanted mice (bottom). Average weight of TC71 (B) and A4573 (D) tumors on day 21 and 17, respectively. Error bars represent SD.
indicating that the migration and differentiation of myeloid cells was not impaired following deletion of Mekk3.

**Effect of downregulating Mekk3 in TC71 cells on tumor growth and tumor vessel formation.** We have shown that deletion of Mekk3 in BM cells impairs their ability to participate in tumor vessel expansion, resulting in decreased tumor vascular density and mural cells/pericyte coverage. To determine whether tumor cell expression of Mekk3 is required for tumor-induced vessel expansion, Mekk3 in TC71 cells was knocked down using siRNA. Two stable clones were isolated (TC71 clone 8 and TC71 clone 10; Fig. 6A).

The downregulation of Mekk3 in the TC71 cells had no effect on the ability of these cells to form tumors or stimulate neovascularization. Tumor growth and MVD were similar to the control-transfected cells (Fig. 6B and C). Tumors were harvested on day 25 to confirm that the Mekk3 downregulation had been maintained (Fig. 6D).

**Discussion**

Tumor vessels are formed through at least two different processes: angiogenesis (2, 4, 26), defined as endothelial cell
proliferation from the preexisting vasculature, and vasculogenesis (2, 3, 27), defined as the recruitment of BM-derived precursors into the tumor area with subsequent differentiation into endothelial cells. The contribution of vasculogenesis varies considerably depending on the tumor type. We have shown that vasculogenesis, in addition to angiogenesis, contributes to the expansion of the Ewing’s tumor vascular network with 10% of the vessels containing BM-derived as opposed to locally derived cells (6, 7, 28). Using a transplant mouse model with GFP+ BM cells, we showed that both locally derived and BM-derived cells make up the tumor vessel wall and the surrounding pericyte population (7, 28). Our previous studies (6, 7, 28) support the concept that BM cells contribute to the endothelial and peri-endothelial components that form the Ewing’s tumor vasculature. Inhibiting BM cell chemotaxis into the tumor area resulted in the formation of significantly smaller and less vascular tumors (28). Furthermore, stimulating the migration of BM cells into vascular endothelial growth factor (VEGF)–inhibited Ewing’s tumors in vivo enhanced the neo-vasculature development and rescued tumor growth (29). Taken together, these data indicated that the vasculogenesis process is vital in the formation of tumor vessels.

Recent studies have questioned the importance of vasculogenesis to tumor development and growth (20). Proving that vasculogenesis is a critical process in tumor vessel expansion requires a model in which angiogenesis is intact but vasculogenesis is impaired. In the study presented here, we elected to take advantage of the recent finding that the Mekk3 gene is required for blood vessel development (12). We first confirmed that Mekk3Δflox/− cells failed to form vessels. Next, we transplanted Mekk3Δflox/− BM cells into lethally irradiated nude mice, thereby creating a mouse that had Mekk3Δflox/− cells in the peripheral organs (cells that could participate in angiogenesis) and Mekk3Δflox/− cells in the BM (cells that could not participate in vasculogenesis). The absence of Mekk3 did not affect engraftment. Mice survived the irradiation procedure and engraftment was confirmed 4 weeks after transplant. BM cells from the Mekk3Δflox/− BM–transplanted mice were negative for Mekk3, as assessed by both genotyping and Western blot (Fig. 3). Mice transplanted with Mekk3Δflox/+ BM cells were positive for Mekk3 and served as the controls. Tumor growth was significantly impaired in the Mekk3Δflox/− BM–transplanted mice (Fig. 4). Although tamoxifen was used to generate and maintain the Mekk3Δflox/− status in the BM cells, tamoxifen treatment played no role in this tumor suppression as both the Mekk3Δflox/+ and Mekk3Δflox/− BM–transplanted mice received identical tamoxifen treatment. The tumors from the

![Figure 6](image-url)

Figure 6. Downregulation of Mekk3 in TC71 cells did not affect tumor growth or tumor vessel formation. TC71 cells were transfected with Mekk3 siRNA. Several clones were isolated following transfection. A, downregulation of Mekk3 was confirmed by Western blot in clone 8 and clone 10. B, mice were injected with TC71, TC71 control siRNA transfected (si-control), clone 8, or clone 10 cells. Tumor growth was monitored for 4 wk. C, tumors were excised on day 25 and analyzed by immunohistochemistry using CD31 staining. The average number of vessels was quantified by counting five random high-power microscopic fields from different tumor sections. Error bars represent SD. D, excised tumors were also analyzed by Western blot for Mekk3 expression.
Mekk3Δfloxs/− BM–transplanted mice remained small for over 2 weeks (Fig. 4A and C). These tumors were less vascular with a significant decrease in MVD and pericyte coverage (Fig. 5). Chemotaxis of the Mekk3Δfloxs/− BM cells into the tumor area was not impaired. The Mekk3Δfloxs/− and Mekk3ΔΔfloxs/− cells were LacZ+, allowing us to identify BM-derived cells in the tumor tissue using β-gal staining. Tumor sections from the BM-transplanted mice showed LacZ+ cells with significant numbers of LacZ+/CD31+ double-positive cells, indicating that BM cells were migrating into the tumor area, differentiating into endothelial cells, and participating in tumor vessel formation. Whereas LacZ+ cells were also identified in tumor sections from the Mekk3Δfloxs/− BM–transplanted mice, the number of LacZ+/CD31+ double-positive cells was significantly diminished (Fig. 5). These data suggest that the Mekk3Δfloxs− BM cells were able to migrate to the tumor but unable to participate in vessel formation. This resulted in few BM-derived tumor vessels, confirming the selective inhibition of vasculogenesis. The vessels that were present were derived from the host cells in the surrounding tumor area as they were LacZ−. Our data show for the first time that selectively inhibiting vasculogenesis severely compromised tumor growth.

The transplant model used to selectively inhibit BM cell participation in tumor vessel formation required whole-body irradiation. Radiation has been shown to inhibit local angiogenesis to some degree (30). Although we cannot exclude the fact that the level of angiogenesis may have been decreased in the mice after radiation, the level of angiogenesis was the same in the Mekk3Δfloxs/+ and Mekk3ΔΔfloxs/− BM–transplanted mice. Therefore, radiation effect cannot explain the decreased tumor growth rate seen. We confirmed this by quantifying the number of tumor vessels that contained no BM-derived cells. This was done by identifying the CD31+/LacZ− tumor vessels. Both the Mekk3Δfloxs/− and Mekk3ΔΔfloxs/− BM cells were LacZ+. Therefore, a vessel that contained no LacZ− cells was derived by the local endothelial cells or angiogenesis. Vasculogenesis contributed to the LacZ− vessels. The number of CD31+/LacZ− vessels was not significantly different in the Mekk3Δfloxs/+ and Mekk3ΔΔfloxs/− BM–transplanted mice (P > 0.05). These data confirmed that the decreased tumor growth rate seen in the Mekk3Δfloxs−–transplanted mice using both the TC71 and A4573 models was a direct effect of defective vasculogenesis and the inability of BM cells to participate in tumor vessel formation. Although our model may favor vasculogenesis, this does not lessen the importance of our finding. Exponential tumor growth was seen in the irradiated mice transplanted with Mekk3ΔΔfloxs/− BM cells that can participate in vasculogenesis, whereas the tumors in the Mekk3Δfloxs−–transplanted mice remained unchanged in size (Fig. 4). If anything, this shows that vasculogenesis may provide a mechanism for tumor cells to circumvent the negative effect of radiation on angiogenesis, thereby rescuing tumor growth.

Our studies indicate that tumor vessel expansion and tumor growth are compromised when BM cells are unable to participate in tumor vascular formation. Altering Mekk3 expression in the TC71 tumor cells had no effect on tumor growth. This is not surprising because altering the status of Mekk3 in tumor cells does not affect VEGF production or the ability of cells in the microenvironment to form vessel (31). Both the local endothelial cells and the BM cells in this model are Mekk3+/− and can therefore participate in tumor vessel formation. These data indicate that the status of Mekk3 in the tumor cell itself is of no consequence to the development of the tumor vasculature.

Others have shown that the growth of Mekk3 deficient tumor-like embryonic stem cells was similar to Mekk3+/− embryonic stem cells (31). MVD was also not affected. This supports our findings that the status of Mekk3 in tumor cells does not affect tumor-induced vessel formation. However, this study did not examine whether Mekk3 deletion in the microenvironment affected tumor growth or tumor vessel formation. Our current study examined both.

In summary, we have shown that MEKK3 plays a key role in the ability of BM stem cells to participate in the formation of tumor vessels, which subsequently significantly affect tumor growth. We also showed that MEKK3 may control critical signaling pathways that are involved in pericyte differentiation and interaction with the vascular endothelium. Finally, we showed for the first time that vasculogenesis and BM cells not only contribute to, but play a critical role in, the development and the expansion of the tumor vascular network that supports the growth of Ewing’s tumors. The importance of BM-derived vasculogenesis has also been shown in other tumor models (32, 33). Inhibiting this process suppresses the ability of Ewing’s sarcoma cells to grow. These are important new findings particularly for Ewing’s sarcoma, as cure rates have remained stagnant for >20 years. In addition, the long-term effects associated with intensive chemotherapy and radiation underscores the need for more targeted approaches. Targeting the vasculogenesis process may therefore offer novel therapeutic opportunities.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Thomas Ludwig (Columbia University, New York, NY) for providing the Cre-ER mice.

L. Yu performed research, designed experiments, analyzed data, and co-wrote the paper; B. Su helped to design the experiments and co-wrote the paper; M. Hollomon, Y. Deng, and V. Facchinetti performed research; E.S. Kleinerman conceived and designed the research and co-wrote the paper.

Grant Support

National Cancer Institute grants ROI 103986 (E.S. Kleinerman), core grant CA 16672, and NIH grant HL070225 (B. Su).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/27/09; revised 11/24/09; accepted 12/3/09; published OnlineFirst 2/2/10.
BM Cells Are Critical for Tumor Vessel Expansion

References


Vasculogenesis Driven by Bone Marrow-Derived Cells Is Essential for Growth of Ewing's Sarcomas

Ling Yu, Bing Su, Mario Hollomon, et al.

Cancer Res 2010;70:1334-1343. Published OnlineFirst February 2, 2010.

Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-2795

This article cites 33 articles, 12 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/4/1334.full#ref-list-1

This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/70/4/1334.full#related-urls

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/70/4/1334.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.